Key result
Deactivation of tachycardia therapies only resulted in similar rates of death within 1 month compared to deactivation of bradycardia therapies (85% vs 94%; P=.37).
Why the study?
What are the features and outcomes of patients who undergo cardiovascular implantable electronic device deactivation?
Population
150 patients who underwent cardiovascular implantable electronic device deactivation, median age 79 years…
Design
Cohort
Follow-up
1 month
Authors
Loading...
Similar 1-month mortality after tachycardia-only vs bradycardia deactivation; leaves open optimal CIED management at end of life.
Observational (n=150)
No
What are the features and outcomes of patients who undergo cardiovascular implantable electronic device deactivation?
Absolute Event Rate: 85% vs 94%
p-value: p=.37
Most CIED deactivations are for tachycardia therapies, often requested by surrogates, and are followed by death shortly after, highlighting the need for advance care planning regarding device management.
Buchhalter et al. (2013) conducted an observational in Cardiovascular implantable electronic device deactivation (n=150). Deactivation of tachycardia therapies only vs. Deactivation of bradycardia therapies with or without tachycardia therapies was evaluated on Death within 1 month of device deactivation (p=.37). Deactivation of tachycardia therapies only resulted in similar rates of death within 1 month compared to deactivation of bradycardia therapies (85% vs 94%; P=.37).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: